319 related articles for article (PubMed ID: 19483050)
1. Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
Brambilla E; Gazdar A
Eur Respir J; 2009 Jun; 33(6):1485-97. PubMed ID: 19483050
[TBL] [Abstract][Full Text] [Related]
2. Molecular abnormalities in lung cancer.
Salgia R; Skarin AT
J Clin Oncol; 1998 Mar; 16(3):1207-17. PubMed ID: 9508209
[TBL] [Abstract][Full Text] [Related]
3. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
Oncogene; 2013 Feb; 32(8):1050-8. PubMed ID: 22450744
[TBL] [Abstract][Full Text] [Related]
4. The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.
Li Z; Ivanov AA; Su R; Gonzalez-Pecchi V; Qi Q; Liu S; Webber P; McMillan E; Rusnak L; Pham C; Chen X; Mo X; Revennaugh B; Zhou W; Marcus A; Harati S; Chen X; Johns MA; White MA; Moreno C; Cooper LA; Du Y; Khuri FR; Fu H
Nat Commun; 2017 Feb; 8():14356. PubMed ID: 28205554
[TBL] [Abstract][Full Text] [Related]
5. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
7. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
8. The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer.
Lai YH; Yu SL; Chen HY; Wang CC; Chen HW; Chen JJ
Carcinogenesis; 2013 May; 34(5):1069-80. PubMed ID: 23306212
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.
Tseng RC; Lin RK; Wen CK; Tseng C; Hsu HS; Hsu WH; Wang YC
Oncogene; 2008 Jul; 27(32):4488-96. PubMed ID: 18372914
[TBL] [Abstract][Full Text] [Related]
10. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes.
Bergh JC
Am Rev Respir Dis; 1990 Dec; 142(6 Pt 2):S20-6. PubMed ID: 2174659
[TBL] [Abstract][Full Text] [Related]
11. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
13. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.
Fallet V; Saffroy R; Girard N; Mazieres J; Lantuejoul S; Vieira T; Rouquette I; Thivolet-Bejui F; Ung M; Poulot V; Schlick L; Moro-Sibilot D; Antoine M; Cadranel J; Lemoine A; Wislez M
Ann Oncol; 2015 Aug; 26(8):1748-53. PubMed ID: 25969368
[TBL] [Abstract][Full Text] [Related]
14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
15. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
16. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
[TBL] [Abstract][Full Text] [Related]
19. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
[TBL] [Abstract][Full Text] [Related]
20. [Thyroid transcription factor-1 level is associated with epidermal growth factor receptor mutation status in patients with advanced lung adenocarcinoma].
Niu Y; Wang H; Zhang G; Ma J; Wei B; Ma Z
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):919-23. PubMed ID: 25609130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]